Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 24, Issue 2, 2006, Pages 217-227

  Jubb, Adrian M ^a   Hurwitz, Herbert I ^a   Bai, Wei ^a   Holmgren, Eric B ^a   Tobin, Patti ^a   Guerrero, A Steven ^a   Kabbinavar, Fairooz ^a   Holden, Scott N ^a   Novotny, William F ^a   Frantz, Gretchen D ^a   Hillan, Kenneth J ^a   Koeppen, Hartmut ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PLACEBO; THROMBOSPONDIN 2; VASCULOTROPIN A; ANTINEOPLASTIC AGENT; MESSENGER RNA; MONOCLONAL ANTIBODY; THROMBOSPONDIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN;

ADULT; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROVASCULATURE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TISSUE MICROARRAY; TREATMENT OUTCOME; COLORECTAL TUMOR; DRUG ANTAGONISM; GENETICS; MICROCIRCULATION; MIDDLE AGED; MORTALITY; VASCULARIZATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROCIRCULATION; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RNA, MESSENGER; THROMBOSPONDINS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33644823334     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.5388     Document Type: Article

References (70)

1. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997
2. Jubb AM, Pham TQ, Hanby AM, et al: Expression of vascular endothelial growth factor, hypoxia inducible factor 1 alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol 57:504-512, 2004
3. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993
4. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2:533-543, 2001
5. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
6. Cascinu S, Graziano F, Catalano V, et al: An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer: Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation. Br J Cancer 86:744-749, 2002
7. Galizia G, Lieto E, Ferraraccio F, et al: Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 10:3490-3499, 2004
8. Kaio E, Tanaka S, Kitadai Y, et al: Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 64:61-73, 2003
9. Khorana AA, Ryan CK, Cox C, et al: Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with stage II and stage III colon carcinoma: A role for the host response in prognosis. Cancer 97:960-968, 2003
10. Konno H, Abe J, Kaneko T, et al: Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer. Jpn J Cancer Res 92:516-523, 2001
11. Kuwai T, Kitadai Y, Tanaka S, et al: Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer 105:176-181, 2003
12. Lee JC, Chow NH, Wang ST, et al: Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36:748-753, 2000
13. Maeda K, Nishiguchi Y, Yashiro M, et al: Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med 5:373-378, 2000
14. Davies MM, Jonas SK, Kaur S, et al: Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver mestastasis vascularity and volume. Br J Cancer 82:1004-1008, 2000
15. Hyodo I, Doi T, Endo H, et al: Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 34:2041-2045, 1998
16. Kumar H, Heer K, Lee PW, et al: Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 4:1279-2185, 1998
17. Lissoni P, Rovelli F, Malugani F, et al: Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer. Int J Biol Markers 18:152-155, 2003
18. Nakayama Y, Sako T, Shibao K, et al: Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer. Anticancer Res 22:2437-2442, 2002
19. Takeda A, Shimada H, Imaseki H, et al: Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: Correlation with clinicopathological factors and tumor markers. Oncol Rep 7:333-338, 2000
20. Werther K, Sorensen S, Christensen IJ, et al: Circulating vascular endothelial growth factor six months after primary surgery as a prognostic marker in patients with colorectal cancer. Acta Oncol 42: 837-845, 2003
21. Werther K, Christensen IJ, Nielsen HJ: Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 86:417-423, 2002
22. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
23. Adams JC: Thrombospondins: Multifunctional regulators of cell interactions. Annu Rev Cell Dev Biol 17:25-51, 2001
24. Bein K, Simons M: Thrombospondin type 1 repeats interact with matrix metalloproteinase 2: Regulation of metalloproteinase activity. J Biol Chem 275:32167-32173, 2000
25. Iruela-Arispe ML, Lombardo M, Krutzsch HC, et al: Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 100:1423-1431, 1999
26. Simantov R, Febbraio M, Bornstein P, et al: The anti-angiogenic activity of thrombospondin-2 (TSP-2) is mediated by CD36: Evidence that the CD36 anti-angiogenic response may be activated by a family of thrombospondin type I repeat (TSR) domain proteins. Blood 98:822A, 2001 (abstr 3415)
27. Allegrini G, Goulette FA, Darnowski JW, et al: Thrombospondin-1 plus irinotecan: A novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol 53:261-266, 2004
28. Bocci G, Francia G, Man S, et al: Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 100:12917-12922, 2003
29. Kyriakides TR, Leach KJ, Hoffman AS, et al: Mice that lack the angiogenesis inhibitor, thrombospondin 2, mount an altered foreign body reaction characterized by increased vascularity. Proc Natl Acad Sci U S A 96:4449-44954, 1999
30. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, et al: Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A 98:12485-12490, 2001
31. Streit M, Riccardi L, Velasco P, et al: Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci U S A 96:14888-14893, 1999
32. Streit M, Stephen AE, Hawighorst T, et al: Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy. Cancer Res 62:2004-2012, 2002
33. Tokunaga T, Nakamura M, Oshika Y, et al: Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br J Cancer 79:354-359, 1999
34. Tomii Y, Kamochi J, Yamazaki H, et al: Human thrombospondin 2 inhibits proliferation of microvascular endothelial cells. Int J Oncol 20:339-342, 2002
35. Volpert OV, Tolsma SS, Pellerin S, et al: Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun 217:326-332, 1995
36. Werther K, Christensen IJ, Brunner N, et al: Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma: The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol 26:657-662, 2000
37. Oshika Y, Masuda K, Tokunaga T, et al: Thrombospondin 2 gene expression is correlated with decreased vascularity in non-small cell lung cancer. Clin Cancer Res 4:1785-1788, 1998
38. Seki N, Kodama J, Hashimoto I, et al: Thrombospondin-1 and -2 messenger RNA expression in normal and neoplastic endometrial tissues: Correlation with angiogenesis and prognosis. Int J Oncol 19:305-310, 2001
39. Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847, 1998
40. Frantz GD, Pham TQ, Peale FV Jr, et al: Detection of novel gene expression in paraffin-embedded tissues by isotopic in situ hybridization in tissue microarrays. J Pathol 195:87-96, 2001
41. Jubb AM, Landon TH, Burwick J, et al: Quantitative analysis of colorectal tissue microarrays by immunofluorescence and in situ hybridization. J Pathol 200:577-588, 2003
42. Lu LH, Gillett NA: An optimized protocol for in situ hybridization using PCR-generated 33P-labeled probes. Cell Vis 1:169-176, 1994
43. Chalkley HW: Method for the quantitative morphologic analysis of tissues. J Natl Cancer Inst 4:47-53, 1943
44. Fox SB, Leek RD, Weekes MP, et al: Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 177:275-283, 1995
45. Frank RE, Saclarides TJ, Leurgans S, et al: Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 222:695-699, 1995
46. Takebayashi Y, Akiyama S, Akiba S, et al: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88: 1110-1117, 1996
47. Zheng S, Han MY, Xiao ZX, et al: Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma. World J Gastroenterol 9:1227-1230, 2003
48. Kim KJ, Li B, Houck K, et al: The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7:53-64, 1992
49. Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599, 1997
50. Ferrara N, Hillan KJ, Gerber HP, et al: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400, 2004
51. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004
52. Berney CR, Yang JL, Fisher RJ, et al: Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator. Anticancer Res 18:973-977, 1998
53. Nanni O, Volpi A, Frassineti GL, et al: Role of biological markers in the clinical outcome of colon cancer. Br J Cancer 87:868-875, 2002
54. Cascinu S, Graziano F, Catalano V, et al: Vascular endothelial growth factor and p53 expressions in liver and abdominal metastases from colon cancer. Tumour Biol 24:77-81, 2003
55. Cascinu S, Graziano F, Catalano V, et al: Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer: Implications for the treatment with VEGF inhibitors. Clin Exp Metastasis 18:651-655, 2000
56. Kuramochi H, Hayashi K, Uchida K, et al: Gene expression of vascular endothelial growth factor (VEGF) in primary colorectal cancer and corresponding liver metastases. Proc Amer Assoc Cancer Res 46, 2005 (abstr 5628)
57. Kodama J, Hashimoto I, Seki N, et al: Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor. Anticancer Res 21:2983-2987, 2001
58. Bossi P, Viale G, Lee AK, et al: Angiogenesis in colorectal tumors: Microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res 55:5049-5053, 1995
59. Benjamin LE, Hemo I, Keshet E: A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125:1591-1598, 1998
60. Berger F, Bouamrami A, Gay E, et al: SELDITOF proteomic patterns of human and experimental brain tumors: Potential for new biomarkers and for pharmaco-proteomic endpoints in anti-angiogenic therapy. Eur J Cancer 38:S73, 2002 (abstr 227)
61. DePrimo SE, Wong LM, Khatry DB, et al: Expression profiling of blood samples from an SU5416 phase III metastatic colorectal cancer clinical trial: A novel strategy for biomarker identification. BMC Cancer 3:3, 2003
62. Morimoto AM, Tan N, West K, et al: Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene 23:1618-1626, 2004
63. Morgan B, Thomas AL, Drevs J, et al: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 21:3955-3964, 2003
64. LeCouter J, Kowalski J, Foster J, et al: Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 412:877-884, 2001
65. Relf M, LeJeune S, Scott PA, et al: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor befa-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-969, 1997
66. Bergers G, Javaherian K, Lo KM, et al: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808-812, 1999
67. Bergers G, Song S, Meyer-Morse N, et al: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295, 2003
68. Erber R, Thurnher A, Katsen AD, et al: Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J 18:338-340, 2004
69. Gerber HP, Kowalski J, Sherman D, et al: Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60:6253-6258, 2000
70. Jayson GC, Parker GJ, Mullamitha S, et al: Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23:973-981, 2005